Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma

PHASE3RecruitingINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

September 18, 2026

Conditions
Perennial Allergic Rhinitis Accompanied by Asthma
Interventions
DRUG

Experimental

"1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks~2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks"

DRUG

Comparator

"1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks~2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks"

Trial Locations (1)

Unknown

RECRUITING

Konkuk University Medical Center, Seoul

All Listed Sponsors
lead

Daewon Pharmaceutical Co., Ltd.

INDUSTRY

NCT07168473 - Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma | Biotech Hunter | Biotech Hunter